SCHEMBL6978563

SCHEMBL6978563

CC(C)[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)N1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 7/20 0.50
KMT2A Q03164 4/20 0.48
SMN1; SMN2 Q16637 1/20 0.47
TSHR P16473 2/20 0.47
LMNA P02545 2/20 0.46
ALDH1A1 P00352 1/20 0.46
HTT P42858 1/20 0.46
KCNH2 Q12809 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
AKR1C3 P42330 1/20 0.43
ADAM10 O14672 1/20 0.42
MMP12 P39900 1/20 0.42
MMP13 P45452 1/20 0.42
ADAM17 P78536 1/20 0.42
LIPE Q05469 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981698 0.90 CCR1 (0.47) CCR1KMT2ASMN1; SMN2LMNAALDH1A1
SCHEMBL6979020 0.89 SMN1; SMN2 (0.49) CCR1KMT2ASMN1; SMN2ALDH1A1AKR1C3
SCHEMBL6979028 0.89 SMN1; SMN2 (0.49) CCR1KMT2ASMN1; SMN2ALDH1A1AKR1C3
SCHEMBL6985309 0.85 CAPN1 (0.54) CCR1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6981807 0.82 SMN1; SMN2 (0.43) CCR1KMT2ASMN1; SMN2ALDH1A1AKR1C3
SCHEMBL8405526 0.81 SMN1; SMN2 (0.42) KMT2ASMN1; SMN2TSHRLMNAALDH1A1
SCHEMBL6984615 0.81 KMT2A (0.51) CCR1KMT2ASMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL6981151 0.79 TGM2 (0.45) KMT2ASMN1; SMN2ALDH1A1AKR1C3ADAM10
SCHEMBL6982389 0.79 TGM2 (0.47) CCR1KMT2ASMN1; SMN2ALDH1A1AKR1C3
SCHEMBL6978571 0.79 KMT2A (0.44) KMT2ASMN1; SMN2TSHRLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed